M&A Deal Summary |
|
|---|---|
| Date | 2019-01-03 |
| Target | Celgene |
| Sector | Life Science |
| Buyer(s) | Bristol-Myers Squibb |
| Deal Type | Add-on Acquisition |
| Deal Value | 74.0B USD |
| Advisor(s) | J.P. Morgan Securities Citi (Financial) Wachtell, Lipton, Rosen & Katz (Legal) |
SEARCH BY
| Category | Company |
|---|---|
| Founded | 1887 |
| Sector | Life Science |
| Employees | 34,100 |
| Revenue | 48.3B USD (2024) |
Bristol-Myers Squibb is a life science company engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products on a global basis. Bristol-Myers Squibb was incorporated in 1887 and is based in Princeton, New Jersey.
| DEAL STATS | # |
|---|---|
| Overall | 17 of 25 |
| Sector: Life Science M&A | 17 of 25 |
| Type: Add-on Acquisition M&A Deals | 16 of 23 |
| State: New Jersey M&A | 2 of 2 |
| Country: United States M&A | 14 of 22 |
| Year: 2019 M&A | 1 of 1 |
| Size (of disclosed) | 1 of 21 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2018-10-08 |
Upsa
France Upsa is a provider of an over-the-counter drugs business. Upsa is based in France. |
Sell | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2019-06-19 |
Bristol-Myers Squibb Co. - Anagni Manufacturing Facility
Anagni, Italy Bristol-Myers Squibb Co. - Anagni Manufacturing Facility is a provider of oral solid, biologics, and sterile product manufacturing and packaging facility. |
Sell | - |